Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

Objective This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) tri...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Ming-Jui Hung, Edward Chia-Cheng Lai, Shih-Chieh Shao, Yi-Han Lin, Kai-Cheng Chang, Yuk-Ying Chan, Yea-Huei Kao Yang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMJ Publishing Group 2019-05-01
Serie:	BMJ Open Diabetes Research & Care
Accesso online:	https://drc.bmj.com/content/7/1/e000742.full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!